Oct 17 (Reuters) - SAGE Therapeutics Inc :
* SAGE THERAPEUTICS ANNOUNCES STRATEGIC REORGANIZATION TO PRIORITIZE ZURZUVAE® COMMERCIALIZATION AND FOCUS ITS DEVELOPMENT PORTFOLIO
* SAGE THERAPEUTICS INC - TO REDUCE WORKFORCE BY APPROXIMATELY 33%
* SAGE THERAPEUTICS INC - REORGANIZATION TO IMPACT OVER 165 EMPLOYEES
* SAGE THERAPEUTICS INC - EXPECTS NON-RECURRING CHARGE OF $26M-$28M
* SAGE THERAPEUTICS INC - CHRIS BENECCHI TO BECOME CHIEF OPERATING OFFICER
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。